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Background: Psychotic depression (PD) is a prevalent, severe, under-diagnosed and often inadequately
treated mental disorder, which has received disproportionally little attention by clinicians, researchers
and the pharmaceutical industry. Consequently, the evidence base for optimal clinical practice
regarding PD is limited. The aim of this study was to investigate the degree of consensus among
international treatment guidelines on PD and to determine whether a potential lack of consensus would
be reﬂected in the clinical practice of Danish psychiatrists.
Methods:
1. Review and comparison of international guidelines on the treatment of PD.
2. Questionnaire based survey regarding Danish psychiatrists’ treatment of PD.ll r
þ45
eadResults: The nine international treatment guidelines considered in the review have contrasting opinions on
the optimal treatment for PD: 6 of 9 suggest antidepressant (AD)þantipsychotic (AP) combination therapy,
3 of 9 recommend AD monotherapy and 5 of 9 ﬁnd electroconvulsive therapy (ECT) equally appropriate as
ﬁrst line treatment. The 113 surveyed psychiatrists displayed the same lack of consensus. Their preferred
treatment was either ADþAP combination therapy (42%), AD monotherapy (31%) or ECT (21%). The ﬁrst
line choices of ADs and APs were tricyclic antidepressants (51%) and quetiapine (62%), respectively.
Limitations: The survey data are subjected to a potential selection bias as the respondents are likely to
represent the more informed fraction of psychiatrists.
Conclusions: Our results indicate that both treatment algorithms and clinical practice regarding PD are
highly heterogeneous. This ﬁnding emphasizes the need for further studies on the treatment of psychotic
depression.
& 2012 Elsevier B.V. All rights reserved.1. Introduction
Depression with psychotic symptoms, or ‘‘psychotic depres-
sion’’ (PD), is characterized by the presence of hallucinations and/
or delusions in conjunction with depression. PD differs from non-
psychotic depression (non-PD) in a number of ways, beyond the
presence of psychotic symptoms, as it has a distinct depressive
symptom proﬁle (Maj et al., 2007; Østergaard et al., 2012a, 2012b)
and is associated with higher rate of recurrence (Goldberg and
Harrow, 2004), more psychosocial impairment (Coryell et al.,ights reserved.
72137235.
holm).1996), decreased quality of life (Cramer et al., 2010) and higher
mortality rates (Vythilingam et al., 2003) than non-psychotic
depression. PD is a prevalent condition as demonstrated by studies
from both Europe and the USA, which suggest that approximately
15–20% of the cases fulﬁlling criteria for major depressive episode
are of the psychotic subtype (Johnson et al., 1991; Ohayon and
Schatzberg, 2002).
Currently PD is classiﬁed as a subtype of severe depression in
both major diagnostic guidelines, namely the Diagnostic and Statis-
tical Manual of Mental Disorders, 4th edition (DSM-IV) (American
Psychiatric Association (APA), 2000) and the International Classiﬁca-
tion of Disease, 10th revision (ICD-10) (World Health Organization,
1993). As a likely consequence of the rather peripheral placement in
the diagnostic manuals, PD has not been studied to the same extent
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and remains an underdiagnosed (Rothschild et al., 2008) and
probably undertreated mental disorder (Andreescu et al., 2007).
Randomized control trials (RCT) of both acute and long-term
treatment of PD are rare (Meyers et al., 2006). This is probably
due to a combination of many factors, i.e., the classiﬁcation of
PD as a sub-diagnosis of depression, difﬁculties inherent to the
recruitment of subjects with psychotic disorders for clinical trials
and a general low interest in the disorder from clinicians, re-
searchers, and the pharmaceutical industry. As a result of this
lack of RCTs, and treatment studies in general, the ensuing treat-
ment guidelines for PD are based on relatively sparse evidence
(Rothschild, 2009). This is likely to result in heterogeneous
recommendations and poor consensus regarding the optimal
treatment of PD in clinical practice.
The aim of this study was to investigate potential disparity in
current treatment guidelines on PD and to determine whether
such ambiguity would be reﬂected in general clinical practice and
in the speciﬁc choice of psychopharmacological drugs in the
treatment of PD.Table 1









2010 APA (USA) No No 1 1
2010 NICE (UK) 1 No 2 3nnn
2009 CANMAT (Canada) No No 1 1
2008 TMAP (Texas) No No 1þ 1
2008 SASOP (South Africa) No No 1nþ 22. Methods
2.1. Review of guidelines
Treatment algorithms were selected through a review of the
evidence basis for PD treatment guidelines by Wijkstra et al. (2009)
and in cases where they had been updated after their review, the
most recent edition was considered. In addition to the guidelines
from the review, the Danish algorithm for the treatment of depres-
sion in adults published by the Danish Board of Health (DNBH)
(2007) was also considered due to the setting of the survey. The
guidelines’ recommendations regarding the use of antidepressant
(AD) monotherapy, antipsychotic (AP) monotherapy, ADþAP com-
bination therapy and electroconvulsive therapy (ECT) were assessed
in order to determine the degree of consensus.
2.2. Survey among Danish psychiatrists
A questionnaire was distributed to participants at the annual
meeting of the Danish Psychiatric Association (DPA) in March 2011.
Only psychiatrists/physicians working within the ﬁeld of psychiatry
(from here this group is referred to as ‘‘psychiatrists’’) were asked to
complete the questionnaire, which was designed to obtain informa-
tion that would answer the following questions within the frame-
work of the ICD-10 deﬁnition of unipolar psychotic depression:2007 DNBH (Denmark) 1nn No 2nn 1
2005 DNSC (Netherlands) 1nn No 2nn 1 3nnn
nn nnn1.
2004 RANZCP (Australia &
New Zealand)
No No 1 2
Do psychiatrists treat PD in accordance with established
guidelines?2002 WFSBP No No 1þ 12.(International)What are the preferred antidepressants and antipsychotics
used in the treatment of PD?3. Does suicide risk inﬂuence the choice of treatment in PD?
The abbreviations for the treatment options are: Mono-AD¼monotherapy with an4.
antidepressant, Mono-AP¼monotherapy with an antipsychotic, Combination
ADþAP¼the combination of an antidepressant and an antipsychotic, ECT¼What impression do psychiatrists have of the prevalence, the
suicide risk and their own knowledge of PD?Electroconvulsive Therapy. The acronyms for the treatment guidelines represent5.
the American Psychiatric Association (APA), the National Institute of Clinical
Excellence (NICE), Canadian Network for Mood and Anxiety Treatment (CANMAT),
the Texas Medication Algorithm Project (TMAP), South African Society of Psychia-
trists (SASOP), the Danish National Board of Health (DNBH), the Dutch National
Steering Committee on Multidisciplinary Guideline Development in Mental Health
Care (DNSC), the Royal Australian and New Zealand College of Psychiatrists
(RANZCP) and the World Federation of Societies of Biological Psychiatry (WFSBP).
n Psychotherapy in addition to combination therapy ADþAP.
nn TCA is the preferred AD.
nnn First line choice when severe suicidality or a threatening somatic condition
is present.þ Indicates atypical AP as ﬁrst-line choice. 1 Indicates ﬁrst generation
antipsychotic as ﬁrst-line choice.Are the treatment choices and the impression of PD affected by
experience-level (analysis of experts versus non-experts)?
2.3. Statistical analysis
The data from the questionnaires was transferred to EpiData
(EpiData-Association, 2000) to allow for statistical analysis. Ques-
tions to which the participant gave several answers (against the
instructions given in the questionnaire) were treated as if they
were left blank. To determine whether experience-level affectedthe choice of treatment an ‘‘expert group’’ was deﬁned as the
fraction of respondents who were trained specialists in psychiatry
having treated more than 100 patients with PD. The statistical
analysis was carried out using Stata11 (StataCorp, 2009). All
comparisons were carried out using a two-tailed test of propor-
tions. A signiﬁcance level of 5% was used throughout.3. Results
3.1. Review of guidelines
We assessed the ﬁrst, second and third line treatment sugges-
tions from nine treatment guidelines for psychotic depression
published by the American Psychiatric Association (APA), (2010),
the National Institute For Health and Clinical Excellence (NICE)
(2010), the Canadian Network for Mood and Anxiety Treatment
(CANMAT) (Kennedy et al., 2009; Lam et al., 2009), the Texas
Medication Algorithm Project (TMAP) (Suehs, 2008), the South
African Society of Psychiatrists (SASOP) (2008), the Danish Board
of Health (DNBH) (2007), the Dutch National Steering Committee
Multidisciplinary Guideline Development Mental Health (DNSC)
(2005), the Royal Australian and New Zealand College of
Psychiatrists (RANZCP) (2004) and the World Federation of
Societies of Biological Psychiatry (WFSBP) (Bauer et al., 2002).
An overview of this review is shown in Table 1.
The APA, CANMAT, TMAP and WFSBP guidelines have two ﬁrst
line treatment suggestions, namely either the combination of
ADþAP or ECT. The DNBH guideline suggests either AD mono-
therapy or ECT as ﬁrst line treatment. The SASOP and RANZCP
suggest only the ADþAP combination, while the NICE and DNSC
suggest only AD monotherapy as ﬁrst line treatment. No guideline
suggests AP monotherapy as a treatment option for PD.
The guidelines also provide some speciﬁc recommendations
regarding the class of ADs and APs used in the treatment of PD.
For the ADs, the DNBH, DNSC and the RANZCP advocate the use of
Table 3
First line treatment choice by psychiatrists for
non-suicidal and suicidal psychotic depression.
Treatment choice n¼113 (%)
Non-suicidal Suicidal
ADþAP combination 42 27n
AD monotherapy 31 9nnn
ECT 21 59nnn
AP monotherapy 4 2
Psychotherapy 0 0
Other 0 1
A.K.K. Leadholm, et al. / Journal of Affective Disorders 145 (2013) 214–220216a TCA and TMAP explicitly suggests SSRI or SNRI. The remaining
guidelines provide no speciﬁc advice on which AD to choose, but
recommend selecting a drug based on patient characteristics.
Regarding the APs, only DNSC suggests the use of typical APs
while the SASOP, TMAP and WFSBP endorse the ﬁrst line use of
atypical AP. The remaining guidelines give no speciﬁc advice on
the class of choice. Augmentation with lithium is recommended
by the APA, TMAP and RANZCP guidelines when the initial
pharmacological regimen fails to achieve full remission. The other
guidelines do not mention lithium augmentation in the chapter
dedicated to the treatment of psychotic depression and their
stance in this matter is therefore somewhat unclear.No answer 3 3
Statistical analysis: two-tailed test of proportions.
P-value: no0.05, nno0.01, nnno0.001.3.2. Survey respondents
Out of 250 psychiatrists attending the DPA annual meeting,
and who received the questionnaire, 114 (46%) completed it. Of
these, 1 had not answered any of the demographic questions. This
questionnaire was therefore omitted from the statistical analysis.
The demographics of the 113 participants are listed in Table 2.
The majority of the respondents were psychiatrists (trained
specialists) (76%), were employed at University Hospitals (69%),
working in clinical (73%) or research (11%) positions, and specia-
lized in psychotic (42%) or affective (22%) disorders.Table 2
Demographic data for the participating psychiatrists.
Demographic Category n¼113
Age (mean (SD)) 51 (11)





































No answer 33.3. Psychiatrists’ preferred treatment of PD
The respondents’ answers to the question regarding their ﬁrst
line treatment choice: ‘‘What is your ﬁrst choice of treatment for an
unipolar psychotic depressive patient suffering from delusions of
disease and death? The patient has no known complicating physical
diseases’’ are reported in Table 3.
Psychiatrists were asked to report preferred treatment for both
a non-suicidal and a suicidal patient with PD. In the case of the
non-suicidal patient most respondents preferred the ADþAP
combination therapy (42%) followed by AD monotherapy (31%),
ECT (21%) and AP monotherapy (4%). In the case of a high risk of
suicide, there was a signiﬁcant shift in the preferred treatment
from ADþAP combination therapy (27%), AD monotherapy (9%)
and AP monotherapy (1%) towards ECT (59%).
The respondents’ preferred antidepressants in the treatment of
PD were tricyclic antidepressants (TCA) (51%) followed by the
serotonin–norepinephrine re-uptake inhibitors (SNRIs) (27%) and
the selective serotonin re-uptake inhibitors (SSRIs) (12%). For the
antipsychotics, quetiapine was the drug of choice by the majority
(62%), followed by olanzapine (21%) and risperidone (8%). None of
the psychiatrists would use a ﬁrst-generation antipsychotic as
their ﬁrst choice.
Table 4 shows how psychiatrists evaluate the prevalence of
their use of various treatments in PD compared to non-PD.
The majority reported using TCA (61%), antipsychotics (96%),
ECT (86%) and coercive treatment (against the patient’s will)
(89%) more often in the treatment of PD compared to non-PD.
The opposite was the case for psychotherapy, which was reported
to be used more often in non-PD than in PD by the majority of the
participants (63%).
3.4. Psychiatrists’ clinical impression of PD
The questionnaire also contained a number of questions,
which examined the psychiatrists’ impression/opinion of the
prevalence, the suicide risk and their perceived knowledge of
PD. The phrasing of the questions and the distribution of answers
are listed in Table 5.
A large proportion (40%) of the psychiatrists had the impression
that between 11–20% of severely depressed in/out-patients had
psychotic symptoms, while another 36% reported the prevalence to
be above 20%. The majority (70%) reported that the suicide risk was
higher among PD patients than non-PD patients. Almost one ﬁfth
(19%) answered that they did not have a clear understanding of
the difference between mood-congruent and mood-incongruent
psychotic symptoms in PD. More than a quarter (29%) of the
participants felt that their knowledge of PD was less than their
knowledge of non-PD, bipolar disorder and schizophrenia.
Table 4
Psychiatrists’ use of various treatments in psychotic depression
compared to non-psychotic depression.














































There were 3 answer possibilities for each treatment: ‘‘more often’’
in PD, ‘‘the same’’ in PD and non-PD and ‘‘less often’’ in PD.
n Treatment against the patient’s will.
Table 5
Psychiatrists’ clinical impression of psychotic depression.
Survey question n¼113
(%)
In your experience, what proportion of hospital in/out-patients with severe








Based on your clinical experience, is there a greater risk of suicide amongst





Do you understand the difference between mood-congruent and mood-




Do you feel that your knowledge of psychotic depression is on par with your
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35 respondents fulﬁlled the predeﬁned expert criteria (trained
specialist in psychiatry having treated more than 100 patients
with PD). In the following cases, the answers to the questions
given by the non-experts and the experts, differed signiﬁcantly:
Demographics: A signiﬁcantly larger proportion of experts than
non-experts were found to work primarily in an administrative
function (23% vs. 5%, p¼0.022).
Treatment: A greater proportion of experts than non-experts
reported using TCA more often in the treatment of PD compared
to non-PD (74% vs. 55%, p¼0.044). Regarding ECT, a signiﬁcantly
larger proportion of the non-experts would use ECT as ﬁrst-line
treatment in a non-suicidal patient with PD when compared to
the experts (28% vs. 6%, po0.001). The preferred AD in the
treatment of PD was more often a SSRI among non-experts than
experts (17% vs. 3%, p¼0.0081). For the antipsychotics, the same
was the case for olanzapine (27% vs. 9%, p¼0.010).4. Discussion
This study investigated the degree of consensus regarding the
optimal treatment of psychotic depression both among established
international treatment guidelines and in a sample of Danish
psychiatrists. The main ﬁnding was a high degree of heterogeneity
both in the recommendations given by the guidelines and in the
psychiatrist’s preferred treatment.
4.1. Review of guidelines
The nine different treatment guidelines, covering four con-
tinents and spanning eight years, each represent one of two
central views on the appropriate ﬁrst line pharmacological treat-
ment of psychotic depression, these being either AD monotherapy
or ADþAP combination therapy. The guidelines are based largely
on the same body of literature. However, the DNBH, DNSC and
NICE favor AD monotherapy, as they seem to give more weight,
than the remaining guidelines, to the 2005 Cochrane review of
pharmacological treatment for psychotic depression. The
Cochrane review proved ADþAP combination therapy to be more
effective than AP monotherapy, but not more effective than AD
monotherapy (Wijkstra et al., 2005). Accordingly, some of the
authors behind the Cochrane review (Wijkstra et al., 2009), have
later systematically reviewed the evidence basis of the treatment
guidelines for PD and ranked NICE highest based on the AGREE
rating system (Brouwers et al., 2010).
Among the guidelines, there are also discrepancies regarding
the suggested ﬁrst line AD and AP. The TMAP advocates the ﬁrst-
line use of SSRI/SNRI, while the DNBH, the DNSC and the RANZCP
recommend the use of a TCA as ﬁrst line AD. The remaining
guidelines suggest choosing an AD based on the individual patient
characteristics. The choice of a TCA as ﬁrst line AD by the DNBH
and the DNSC is probably related to the fact that these two
guidelines also advocate AD monotherapy. According to the
Cochrane review from 2005, TCA is more effective than other
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Regarding the antipsychotics, only the DNSC speciﬁcally advo-
cates the use of a typical AP as ﬁrst line, possibly due in part to the
ﬁndings of Spiker et al. (1985). While the APA, RANZCP and TMAP
advocate lithium augmentation in the treatment of PD when the
initial pharmacological treatment does not achieve remission, the
remaining guidelines do not speciﬁcally discuss this aspect. The use of
lithium augmentation in PD is only supported by a relatively limited
body of evidence (Rothschild, 2009). ECT is advocated by most
guidelines as being at least equally effective to the suggested
pharmacological ﬁrst line treatment. Only NICE, RANZCP and DNSC
place ECT as a third and ﬁnal option to be used when other
treatments have failed, or if acute response is required due to medical
comorbidities or suicidality.
The conclusion of this review is that the recommendations given
in the various guidelines are quite heterogeneous—particularly
regarding the optimal pharmacological treatment of PD (monother-
apy with AD versus ADþAP combination therapy). This is probably
due to the relatively limited evidence base on the topic. The Cochrane
review from 2005 states that the lack of statistical evidence for the
superior efﬁcacy of the APþAD combination therapy coupled with
well-known AP side effects constitutes continuing with AD mono-
therapy as the ﬁrst line treatment (Wijkstra et al., 2005). However,
since the publication of the Cochrane review three RCTs on the
pharmacological treatment of PD have been conducted. Two of these
studies point to the superiority of combination therapy compared to
monotherapy: venlafaxine and quetiapine versus venlafaxine alone
(Wijkstra et al., 2010) and olanzapine and sertraline versus olanza-
pine alone (Meyers et al., 2009), while the third study, comparing
amitriptyline and haloperidol versus trimipramine, shows equal
effect (Kunzel et al., 2009). A very recent meta-analysis by Farahani
and Correll, which takes these studies into account, concludes that
the combination of APþAD is signiﬁcantly more effective than not
only AP monotherapy, but now also AD monotherapy in the acute
management of PD (Farahani and Correll, 2012). Future revisions of
treatment guidelines on PD should take the recent evidence of the
superiority of the ADþAP combination into account. However, it
must be noted that until now, no RCTs have clearly demonstrated
that the combination of an atypical AP and a SSRI/SNRI is more
effective than TCA monotherapy. The only study, which has tested
these two regimens against one another did not ﬁnd a signiﬁcant
difference in response (primary outcome), but did detect a difference
in remission (post hoc outcome), favoring the combination of venla-
faxine and quetiapine over imipramine monotherapy. This under-
lines, that the meta-analyses on ADþAP combination treatment
versus AD or AP monotherapy in PD should be interpreted in the
light of a very important methodological limitation: There are
numerous ways of combining an AD and an AP and only a very
limited number of these combinations have been tested in RCTs. The
meta-analyses cited in this paper rely on the assumption that the
effect of the combinations can be compared and summed (class-
effect), despite the use of entirely different ADs and APs in the
individual studies. When considering the heterogeneity of the
pharmacological mechanisms of various ADs and APs this assump-
tion is questionable. Therefore, more head to head studies of speciﬁc
ADþAP combinations are warranted, e.g., comparing the combina-
tions of sertralineþolanzapine (Meyers et al., 2009) and ﬂuoxetine
þolanzapine (Rothschild et al., 2004) to the combination of venla-
faxineþquetiapine (Wijkstra et al., 2010). In these trials, combination
therapy has already been proven more effective than olanzapine and
venlafaxine monotherapies, but the superior ADþAP regimen has yet
to be identiﬁed. Furthermore, the efﬁcacy of a combined treatment
with TCA and a second generation AP (SGA) in comparison with TCA
monotherapy has never been studied in psychotic depression. As the
most recent Cochrane review found TCA to be more effective than
other AD monotherapies (Wijkstra et al., 2005), a trial comparing thecombination of TCA and an atypical AP to TCA monotherapy would
be of interest, as well as a head to head comparison of SSRI/SNRI and
SGA versus TCAþSGA. In addition, given quetiapine’s potential value
as a monotherapy in the treatment of non-psychotic unipolar and
bipolar depression (Chiesa et al., 2012; Pae et al., 2010), studies of its
role in the treatment of PD are highly relevant.
4.2. Psychiatrists’ preferred treatment of PD
In accordance with the general ﬁnding of superior efﬁcacy of the
ADþAP combination in the literature, our survey showed that most
respondents would treat non-suicidal psychotic depression with this
regimen. However, there was a considerable proportion (31%) that
would choose AD monotherapy. This tendency to omit APs in the
treatment of PD has been described previously (Andreescu et al.,
2007).
When examining speciﬁc choices of antidepressants more than
50% of the respondents would choose a TCA. A SNRI was the second
most chosen. The choice of a TCA reﬂects the recommendations given
in the Danish guideline on the treatment of depression in adults
(Danish Board of Health(DNBH), 2007), where TCA monotherapy is
advocated as the ﬁrst line antidepressant for the treatment of PD.
The favored antipsychotic by the Danish psychiatrists was
quetiapine, followed by olanzapine and risperidone. All three are
discussed in the literature on PD and are considered to be valid
treatment options (Goto et al., 2006; Meyers et al., 2009; Wijkstra
et al., 2010). In a study examining the use of antipsychotics in the
treatment of schizophrenia in Denmark, quetiapine, risperidone
and olanzapine were the three most prescribed antipsychotics
(Nielsen et al., 2010). Consequently it seems likely that Danish
psychiatrists prefer some APs compared to others ‘‘across’’ dis-
orders involving psychotic symptoms. Notably, none of the
participants in the survey would administer a classical AP as ﬁrst
line treatment of PD. A similar tendency was seen in the study on
the pharmacological treatment of schizophrenia (Nielsen et al.,
2010). If we assume that Danish psychiatrists would use their
‘‘preferred’’ AD (TCA) and AP (quetiapine) in combination when
treating PD, it is noteworthy that this speciﬁc combination has
never been tested in a clinical trial.
In the case of a high risk of suicide among patients with PD, ECT
became the preferred ﬁrst line treatment compared to AD mono-
therapy and ADþAP combination therapy. NICE, SASOP, DNSC and
RANZCP all advocate this same hierarchy. ECT is suggested as ﬁrst
line treatment option by APA, CANMAT, TMAP, DNBH and WFSBP,
even without the presence of suicidality or acute somatic deteriora-
tion as it is both fast acting and highly effective in PD (Birkenhager
et al., 2003; Loo et al., 2010; Petrides et al., 2001).
The Danish psychiatrists’ more prevalent use of TCA, anti-
psychotics and ECT in the treatment of PD compared to non-PD is
in accordance with the recommendations given in the guideline
by the DNBH (2007). The psychiatrists also reported that they use
coercive treatment more often in PD compared to non-PD. We are
not aware of any other studies assessing this aspect, but speculate
that the combination of ‘‘lack of insight’’ and suicidality, which
are cardinal features in PD (Rothschild, 2009), may underlie this
ﬁnding.
4.3. Psychiatrists’ clinical impression of PD
There was a high degree of consensus regarding the participating
psychiatrists’ perception of the prevalence of the psychotic subtype
among in/out patients with severe depression. More than 60%
believed the prevalence was r20%. However, this is a rather low
estimate compared to a number of studies, which report prevalence
rates in the range of 18–53% among in/outpatients with major
depression depending on the exact clinical setting and the age of the
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PD by the respondents supports previous ﬁndings indicating that
the disorder is frequently missed in clinical practice (Rothschild
et al., 2008).
The vast majority of the Danish psychiatrists believed that the
suicide risk was more pronounced amongst patients with PD
compared to non-PD. This is in accordance with most studies on
this subject (Johnson et al., 1991; Park et al., 2010; Wenzel et al.,
2011), although no ﬁrm conclusion has been made to the
incidence difference or lack thereof (Rothschild, 2009).
Almost 20% of the psychiatrists participating in our survey
reported that they did not have a clear understanding of the
distinction between mood-congruent and mood-incongruent psy-
chotic symptoms in PD. This is obviously problematic as the ICD-
10 allows this subtyping of PD. Some studies have indicated that
mood-incongruence predicts a more severe course of disease
(Coryell and Tsuang, 1985; Coryell et al., 1982), but this remains
controversial (Maj et al., 2007). However if we are to clarify the
prognostic signiﬁcance of mood-congruence vs. mood-
incongruence it is essential that clinicians feel conﬁdent when
distinguishing between the two. The upcoming ICD-11 should
address this issue and provide clear deﬁnitions on this aspect. The
criteria for mood-congruence/incongruence proposed for the
DSM-5 (American Psychiatric Association (APA), 2011) appear to
be very straightforward, easy to apply and could readily be
implemented in the ICD-11, which would also serve the purpose
of decreasing the boundaries between the two diagnostic systems
(Østergaard et al., 2012b). Future studies should aim to outline
differences in the optimal treatment of mood-congruent versus
mood-incongruent psychotic depression, along with the prognos-
tic signiﬁcance of these subgroups.
In relation to the lack of understanding of mood-congruence,
the respondents also reported that their general knowledge of PD
was less than that of non-PD, bipolar disorder and schizophrenia.
This ﬁnding emphasizes the need for increased focus on PD in
order to improve diagnostic sensitivity and treatment of the
disorder.
4.4. Differences between experts and non-experts
The higher preference for the treatment of PD with SSRI, olanza-
pine and ECT among non-experts when compared to the experts may
reﬂect that this younger fraction of physicians, mainly working at
university hospital settings (74%) are more likely to be informed on
the results from recent treatment studies, which favor the combina-
tion of SSRIþolanzapine (Meyers et al., 2009; Rothschild et al., 2004)
and ECT (Birkenhager et al., 2003; Fink, 2003; Petrides et al., 2001).
Furthermore, the current administrative function of many experts
(23%) may also contribute to these differences as these psychiatrists
will have less time available/allocated for clinical practice and
consequently a lesser need to be informed on the latest results from
clinical studies and their impact on the treatment algorithms.
4.5. Limitations
The questions posed in our survey were tested for clarity prior
to the survey, yet there were 5 questionnaires on which some
participants noted their confusion about the wording of the
questions or a lack of answer choices. However, more than 95%
of the participants did not report any difﬁculties regarding the
completion of the questionnaire.
Our results are also limited by a potential selection bias as
only 114 of 250 attending psychiatrists at the annual meeting
completed the questionnaire. Furthermore the 250 attendees
represent a minority of the 1080 members of the Danish Psy-
chiatric Association. However, the main-ﬁnding of the presentstudy, namely that of considerable ambiguity in the treatment of
PD among Danish psychiatrists, is probably only underestimated
by this bias as the participants at the DPA annual meeting are
likely to represent a more well-informed fraction of the ﬁeld.5. Conclusions
The main ﬁnding of this study on the treatment of PD is the
high degree of heterogeneity found both in the recommendations
given by major established treatment guidelines and in the
treatment regimens preferred by Danish psychiatrists. The lack
of consensus is most likely due to the relatively limited evidence
base on this topic and emphasizes the need for further studies on
the treatment of psychotic depression.Role of funding source
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